In this article, Sino Biological discusses emerging targets that are arising within the field of cancer immunotherapy, They also discuss the importance of cancer as a public health threat.
In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.
Chimeric Antigen Receptor - Natural Killer (CAR-NK) cell therapy is an emerging field. Sino Biological produces a wide range of CAR-NK therapeutic and recombinant targets.
Mouse monoclonal antibodies are limited clinically by the HAMA response, as such Sino Biological provides humanization services that massively increase their in vivo tolerability.